ArticleFrontiers in cellular and infection microbiology2022
Omic insights into various ceftazidime-avibactam-resistant
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Therapeutic effect of eravacycline against carbapenem-resistant hypervirulentAntimicrobial agents and chemotherapy · 2026Article
- The Association Between Irritable Bowel Syndrome and Generalized Anxiety Disorder and Influencing Factors: A Mediation Mendelian Randomization Study.Food science & nutrition · 2026Article
- Genomic characterization of ceftazidime/avibactam-resistantFrontiers in microbiology · 2026Article
- OmpK35/36 absence does not confer carbapenem-resistance alone nor ceftazidime-avibactam resistance with oneFrontiers in cellular and infection microbiology · 2026Article
- Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculumAntimicrobial agents and chemotherapy · 2025Article
- Circulation of a UniqueAntibiotics (Basel, Switzerland) · 2025Article
- Sequencing Analysis of Invasive Carbapenem-ResistantMicroorganisms · 2025Article
- BacExplorer: an integrated platform forBioinformatics advances · 2025Article
- Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens.Frontiers in microbiology · 2025Review
- Change in Diagnosis ofAntibiotics (Basel, Switzerland) · 2024Review
- Generation and Characterization of Stable Small Colony Variants of USA300Antibiotics (Basel, Switzerland) · 2024Article
- Evaluation of the causal effects of blood metabolites on irritable bowel syndrome: Mendelian randomization.BMC gastroenterology · 2024Article
- The molecular detection of carbapenem markers with a two-levels amplification screening protocol: epidemiological and resistome insights.Frontiers in microbiology · 2024Article
- Prediction of antimicrobial resistance of Klebsiella pneumoniae from genomic data through machine learning.PloS one · 2024Article
- Review
- Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion.Antibiotics (Basel, Switzerland) · 2023Review
- The Role of Gut Microbiota in the Clinical Outcome of Septic Patients: State of the Art and Future Perspectives.International journal of molecular sciences · 2023Review
- All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches.Antibiotics (Basel, Switzerland) · 2023Review
- Gut microbiota biofilms: From regulatory mechanisms to therapeutic targets.The Journal of experimental medicine · 2023Article
- Efficacy and safety of fecal microbiota transplantation for chronic insomnia in adults: a real world study.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.